Asianet Newsable on MSN
NNVC stock in the limelight after this analyst sees a 350% upside potential – everything to know about its experimental drug for Ebola
The biotech firm said it is progressing towards a Phase II clinical trial of its antiviral drug NV-387 for the Bundibugyo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results